Alantolactone sensitizes human pancreatic cancer cells to EGFR inhibitors through the inhibition of STAT3 signaling

Metabolism and pharmacokinetics of alantolactone and isoalantolactone in rats: Thiol conjugation as a potential metabolic pathway

(2018) Bailun Zhou et al.   JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES

CONKO-005: Adjuvant Chemotherapy With Gemcitabine Plus Erlotinib Versus Gemcitabine Alone in Patients After R0 Resection of Pancreatic Cancer: A Multicenter Randomized Phase III Trial

(2017) Marianne Sinn et al.   JOURNAL OF CLINICAL ONCOLOGY

Alantolactone, a natural sesquiterpene lactone, has potent antitumor activity against glioblastoma by targeting IKKβ kinase activity and interrupting NF-κB/COX-2-mediated signaling cascades

(2017) Xun Wang et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Distinct effects of EGFR inhibitors on epithelial- and mesenchymal-like esophageal squamous cell carcinoma cells

(2017) Masahiro Yoshioka et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Discovery of an Orally Selective Inhibitor of Signal Transducer and Activator of Transcription 3 Using Advanced Multiple Ligand Simultaneous Docking

(2017) Wenying Yu et al.   JOURNAL OF MEDICINAL CHEMISTRY

Current and future therapies for advanced pancreatic cancer

(2017) Rohan Gupta et al.   JOURNAL OF SURGICAL ONCOLOGY

Potential Resistance Mechanisms Revealed by Targeted Sequencing from Lung Adenocarcinoma Patients with Primary Resistance to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs)

(2017) Jia Zhong et al.   Journal of Thoracic Oncology

Vandetanib plus gemcitabine versus placebo plus gemcitabine in locally advanced or metastatic pancreatic carcinoma (ViP): a prospective, randomised, double-blind, multicentre phase 2 trial

(2017) Gary Middleton et al.   LANCET ONCOLOGY

Analysis of natural product regulation of cannabinoid receptors in the treatment of human disease

(2017) S. Badal et al.   PHARMACOLOGY & THERAPEUTICS

SiRNA Delivery with PEGylated Graphene Oxide Nanosheets for Combined Photothermal and Genetherapy for Pancreatic Cancer

(2017) Feng Yin et al.   Theranostics

Seed-in-Soil: Pancreatic Cancer Influenced by Tumor Microenvironment

(2017) Huey-Jen Lin et al.   Cancers

Activation Mechanism of Oncogenic Deletion Mutations in BRAF, EGFR, and HER2

(2016) Scott A. Foster et al.   CANCER CELL

Combined targeting of TGF-β, EGFR and HER2 suppresses lymphangiogenesis and metastasis in a pancreatic cancer model

(2016) Jesse Gore et al.   CANCER LETTERS

Cyclosporine A sensitizes human non-small cell lung cancer cells to gefitinib through inhibition of STAT3

(2016) Jiawei Shou et al.   CANCER LETTERS

Loss of P53 Function Activates JAK2–STAT3 Signaling to Promote Pancreatic Tumor Growth, Stroma Modification, and Gemcitabine Resistance in Mice and Is Associated With Patient Survival

(2016) Sonja M. Wörmann et al.   GASTROENTEROLOGY

YAP1 and TAZ Control Pancreatic Cancer Initiation in Mice by Direct Up-regulation of JAK–STAT3 Signaling

(2016) Ralph Gruber et al.   GASTROENTEROLOGY

PIM-1 contributes to the malignancy of pancreatic cancer and displays diagnostic and prognostic value

(2016) Jianwei Xu et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

EGFR as a Pharmacological Target in EGFR -Mutant Non-Small-Cell Lung Cancer: Where Do We Stand Now?

(2016) E-->-E -->Ke et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Feedback Activation of STAT3 as a Cancer Drug-Resistance Mechanism

(2016) Chengguang Zhao et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer

(2016) Beth O. Van Emburgh et al.   Nature Communications

Mutant KRas-Induced Mitochondrial Oxidative Stress in Acinar Cells Upregulates EGFR Signaling to Drive Formation of Pancreatic Precancerous Lesions

(2016) Geou-Yarh Liou et al.   Cell Reports

Alantolactone selectively suppresses STAT3 activation and exhibits potent anticancer activity in MDA-MB-231 cells

(2015) Jaemoo Chun et al.   CANCER LETTERS

Silibinin and STAT3: A natural way of targeting transcription factors for cancer therapy

(2015) Joaquim Bosch-Barrera et al.   CANCER TREATMENT REVIEWS

Pharmacokinetics, Tissue Distribution and Excretion of Isoalantolactone and Alantolactone in Rats after Oral Administration of Radix Inulae Extract

(2015) Renjie Xu et al.   MOLECULES

Drug Resistance via Feedback Activation of Stat3 in Oncogene-Addicted Cancer Cells

(2014) Ho-June Lee et al.   CANCER CELL

ADAM17-Dependent c-MET-STAT3 Signaling Mediates Resistance to MEK Inhibitors in KRAS Mutant Colorectal Cancer

(2014) Sandra Van Schaeybroeck et al.   Cell Reports

Increased TGF-  as a Mechanism of Acquired Resistance to the Anti-EGFR Inhibitor Cetuximab through EGFR-MET Interaction and Activation of MET Signaling in Colon Cancer Cells

(2013) T. Troiani et al.   CLINICAL CANCER RESEARCH

Discovery of Novel STAT3 Small Molecule Inhibitors via in Silico Site-Directed Fragment-Based Drug Design

(2013) Wenying Yu et al.   JOURNAL OF MEDICINAL CHEMISTRY

EGFR–STAT3 signaling promotes formation of malignant peripheral nerve sheath tumors

(2013) J Wu et al.   ONCOGENE

Targeting Stat3 Abrogates EGFR Inhibitor Resistance in Cancer

(2012) M. Sen et al.   CLINICAL CANCER RESEARCH

Impact of STAT3 Phosphorylation on the Clinical Effectiveness of Anti-EGFR–Based Therapy in Patients With Metastatic Colorectal Cancer

(2012) Erion Dobi et al.   Clinical Colorectal Cancer

Activation of IL-6R/JAK1/STAT3 Signaling Induces De Novo Resistance to Irreversible EGFR Inhibitors in Non-Small Cell Lung Cancer with T790M Resistance Mutation

(2012) S. M. Kim et al.   MOLECULAR CANCER THERAPEUTICS

Fragment-Based Drug Design and Drug Repositioning Using Multiple Ligand Simultaneous Docking (MLSD): Identifying Celecoxib and Template Compounds as Novel Inhibitors of Signal Transducer and Activator of Transcription 3 (STAT3)

(2011) Huameng Li et al.   JOURNAL OF MEDICINAL CHEMISTRY

Met Activation in Non-Small Cell Lung Cancer Is Associated with de Novo Resistance to EGFR Inhibitors and the Development of Brain Metastasis

(2010) Elisa Benedettini et al.   AMERICAN JOURNAL OF PATHOLOGY